Lv5
950 积分 2024-08-29 加入
[177Lu]Lu-XYIMSR-01: A Novel CAIX-Targeted Radiotherapeutic for Enhanced Treatment of Malignant Glioma
17天前
已完结
Multimodal discovery of Bavachinin A: a natural FLT3 agonist for treating thrombocytopenia
23天前
已完结
Preclinical Comparison of [111In]In- and [225Ac]Ac-DOTA-Trastuzumab IgG, F(ab′)2 and Fab for Theranostic SPECT/CT Imaging and α-Particle Radioimmunotherapy of HER2-Positive Human Breast Cancer
1个月前
已完结
[177Lu]Lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models
1个月前
已完结
Radiotheranostic landscape: A review of clinical and preclinical development
1个月前
已完结
A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers
1个月前
已完结
Preclinical dosimetric studies of 177Lu‐scFvD2B and comparison with 177Lu‐PSMA‐617 and 177Lu‐iPSMA endoradiotherapeutic agents
2个月前
已完结
Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer
2个月前
已完结
Response to RL-225Ac in prostate cancer: Effect of prior treatment with RL-177Lu: A systematic review of the literature
2个月前
已完结
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA
2个月前
已完结
皖公网安备34019202002308
